These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 11304936

  • 1. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD.
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [Abstract] [Full Text] [Related]

  • 2. General pharmacology of IY-81149, a new proton pump inhibitor.
    Kim EJ, Lee RK, Lee SM, Kim DY.
    Arzneimittelforschung; 2001 Jan; 51(1):51-9. PubMed ID: 11215326
    [Abstract] [Full Text] [Related]

  • 3. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
    Wallmark B, Lorentzon P, Larsson H.
    Scand J Gastroenterol Suppl; 1985 Jan; 108():37-51. PubMed ID: 2988109
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
    Ito K, Kinoshita K, Tomizawa A, Inaba F, Morikawa-Inomata Y, Makino M, Tabata K, Shibakawa N.
    J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y.
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of gastric acid secretion by omeprazole in the dog and rat.
    Larsson H, Carlsson E, Junggren U, Olbe L, Sjöstrand SE, Skånberg I, Sundell G.
    Gastroenterology; 1983 Oct; 85(4):900-7. PubMed ID: 6884713
    [Abstract] [Full Text] [Related]

  • 8. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
    Yamaguchi T, Aihara K, Yamada S, Narita S, Kogi K.
    Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
    [Abstract] [Full Text] [Related]

  • 9. E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion.
    Kodama K, Fujisaki H, Kubota A, Kato H, Hirota K, Kuramochi H, Murota M, Tabata Y, Ueda M, Harada H, Kawahara T, Shinoda M, Watanabe N, Iida D, Terauchi H, Yasui S, Miyazawa S, Nagakawa J.
    J Pharmacol Exp Ther; 2010 Aug; 334(2):395-401. PubMed ID: 20484556
    [Abstract] [Full Text] [Related]

  • 10. Current status of acid pump antagonists (reversible PPIs).
    Wurst W, Hartmann M.
    Yale J Biol Med; 1996 Aug; 69(3):233-43. PubMed ID: 9165692
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
    Cao H, Wang MW, Sun LX, Ikejima T, Hu ZQ, Zhao WH.
    J Pharm Pharmacol; 2005 Jul; 57(7):923-7. PubMed ID: 15969954
    [Abstract] [Full Text] [Related]

  • 12. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
    Periclou AP, Goldwater R, Lee SM, Park DW, Kim DY, Cho KD, Boileau F, Jung WT.
    Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
    [Abstract] [Full Text] [Related]

  • 13. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
    Kinoshita M, Saito N, Noto T, Tamaki H.
    J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
    [Abstract] [Full Text] [Related]

  • 14. Cyclo-oxygenase-1 inhibition increases acid secretion by modulating H+,K+-ATPase expression and activation in rabbit parietal cells.
    Nandi J, Das PK, Zinkievich JM, Baltodano JD, Levine RA.
    Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):127-34. PubMed ID: 18759857
    [Abstract] [Full Text] [Related]

  • 15. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
    Dammann HG, Burkhardt F.
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antisecretory drugs.
    Okabe S, Shimosako K, Amagase K.
    J Physiol Pharmacol; 2001 Dec; 52(4 Pt 1):639-56. PubMed ID: 11787764
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
    Shin JM, Homerin M, Domagala F, Ficheux H, Sachs G.
    Biochem Pharmacol; 2006 Mar 14; 71(6):837-49. PubMed ID: 16405921
    [Abstract] [Full Text] [Related]

  • 18. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
    Kim KB, Chang MS, Chung YK, Sohn SK, Kim SG, Choi WS.
    J Pharm Pharmacol; 1998 May 14; 50(5):521-9. PubMed ID: 9643446
    [Abstract] [Full Text] [Related]

  • 19. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, Pisegna JR.
    Am J Gastroenterol; 2001 Dec 14; 96(12):3274-80. PubMed ID: 11774936
    [Abstract] [Full Text] [Related]

  • 20. Effects of omeprazole, a substituted benzimidazole, on gastrointestinal secretions, serum gastrin, and gastric mucosal blood flow in dogs.
    Konturek SJ, Cieszkowski M, Kwiecień N, Konturek J, Tasler J, Bilski J.
    Gastroenterology; 1984 Jan 14; 86(1):71-7. PubMed ID: 6689674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.